• Launched in 2016 in Marlow, The Sprintathon has enjoyed great success over the last couple of years raising money for Stand up to Cancer
• The marathon relay that hundreds of people do together in 100m sprints is back in an attempt to beat the marathon world record time
The Sprintathon, the marathon relay that hundreds of people do together in 100m sprints, has come to Bromley, the home of Direct Line Group (DLG) in an attempt to smash the world marathon record time of 2:02:57 set by Dennis Kimetto in 2014.
Launched in Marlow in 2016 by passionate supporter and Marketing Director at Direct Line Group, Mark Evans, the Sprintathon has grown from a one-off charity fundraiser into an ‘off-the-shelf’ event that companies and schools can use as an engaging and rewarding group experience where little bits of greatness can make a big difference to fighting cancer.
On June 7th 422 DLG employees of all shapes, sizes and athletic abilities will run 105.5 consecutive laps of Norman Park Athletics track. Several suppliers are also entering lap teams in what epitomises the “Working Together” ethos of DLG.
Mark Evans, Sprintathon creator and Marketing Director at Direct Line Group, commented, “There are exciting times ahead for the Sprintathon. The concept seems to be infectious and after two years of piloting and practising it’s now reached a stage where more companies and schools can run their own event with minimal support. This year we are set to raise about £100k but I’m sure that in futureyears we can smash that and Beat Cancer Faster.”
Evans added, “It has been inspiring to see so many colleagues pull together to get involved in the Sprintathon and raise funds to support Stand Up To Cancer in their research. Clearly many of our colleagues have been affected by cancer so it’s great that we can do our bit in a fun and collaborative way. Many colleagues will be using their ‘One Day’ paid volunteering charity day which is another reason why DLG is such a great place to work.”
Launched in the UK in 2012, Stand Up To Cancer funds translational research, accelerating new cancer treatments and tests for UK patients to ultimately save more lives.